For Biodexa Pharmaceuticals Plc ADR [BDRX], Analyst sees a rise to $8. What next?

Biodexa Pharmaceuticals Plc ADR [NASDAQ: BDRX] gained 24.14% or 0.35 points to close at $1.80 with a heavy trading volume of 11884324 shares. The company report on February 8, 2024 at 8:30 AM that Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients.

Biodexa Pharmaceuticals PLC.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients.

The daily chart for BDRX points out that the company has recorded -67.97% loss over the past six months.

If we look at the average trading volume of 886.25K shares, BDRX reached to a volume of 11884324 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Biodexa Pharmaceuticals Plc ADR [BDRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BDRX shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BDRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Ladenburg Thalmann have made an estimate for Biodexa Pharmaceuticals Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 08, 2024.

The Average True Range (ATR) for Biodexa Pharmaceuticals Plc ADR is set at 0.31, with the Price to Sales ratio for BDRX stock in the period of the last 12 months amounting to 0.67. The Price to Book ratio for the last quarter was 3.57, with the Price to Cash per share for the same quarter was set at 27.71.

Trading performance analysis for BDRX stock

Biodexa Pharmaceuticals Plc ADR [BDRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.64. With this latest performance, BDRX shares dropped by -10.45% in over the last four-week period, additionally sinking by -67.97% over the last 6 months – not to mention a drop of -99.03% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BDRX stock in for the last two-week period is set at 49.39, with the RSI for the last a single of trading hit 57.83, and the three-weeks RSI is set at 45.23 for Biodexa Pharmaceuticals Plc ADR [BDRX]. The present Moving Average for the last 50 days of trading for this stock 2.3046, while it was recorded at 1.4420 for the last single week of trading, and 5.5595 for the last 200 days.

Biodexa Pharmaceuticals Plc ADR [BDRX]: A deeper dive into fundamental analysis

Biodexa Pharmaceuticals Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.18 and a Current Ratio set at 3.18.

An analysis of Institutional ownership at Biodexa Pharmaceuticals Plc ADR [BDRX]

The top three institutional holders of BDRX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in BDRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in BDRX stock with ownership which is approximately 5.8325%.